Business
TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the third patient in Cohort 4 of its Phase 1a clinical trial has received their initial dose of TTX-MC138. All cohorts have enrolled at least three patients who have been dosed with TTX-MC138 at least once. The Safety Review Committee monitoring the clinical trial unanimously approved opening the fourth cohort based on its review of avai
About this update from Transcode Therapeutics, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"15 patients treated across four escalating dose levels of TTX-MC138","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"No significant safety or dose limiting toxicities reported","length":58,"tagName":"p"}]},{"val":[{"type":"text","content":"10 patients remain on study with no evidence of disease progression","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"PD analysis at 24 hours post-dosing provides evidence of miR-10b target engagement","length":82,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":274,"olType":false},{"type":"text","content":"BOSTON, May 8, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the third patient in Cohort 4 of its Phase 1a clinical trial has received their initial dose of TTX-MC138. All cohorts have enrolled at least three patients who have been dosed with TTX-MC138 at least once. The Safety Review Committee monitoring the clinical trial unanimously approved opening the fourth cohort based on its review of available safety and pharmacokinetic (PK) data. Additionally, the Safety Review Committee approved expanded enrollment in Cohort 3 to obtain additional safety data. To date, 15 patients have received at least one dose of TTX-MC138 at 4 separate dose levels ranging from 0.8 mg/kg to 4.8 mg/kg. Three patients have been treated in the expanded enrollment.","length":886,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/TransCode Therapeutics, Inc.)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/TransCode Therapeutics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":58,"url":"https://media.zenfs.com/en/prnewswire.com/6158e3f623b2cdcf70a213bfe6b5eb12"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/y2kxVj5Zztrmutz6upX.Ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/6158e3f623b2cdcf70a213bfe6b5eb12","width":400,"height":58}},"href":"https://mma.prnewswire.com/media/2583692/TransCode_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Ten patients remain on study for continued treatment, receiving an additional dose of TTX-MC138 during each treatment cycle every 28 da...